Report: Pfizer may make a bid for Protalix

Israel's Protalix BioTherapeutics (PLX) has seen its shares skyrocket 415 percent this year. And its success developing a new Gaucher disease therapy appears to have attracted some intense interest from Pfizer.

Reporters at TheMarker say that a delegation from Pfizer visited Protalix's facilities in Israel in anticipation of a development deal and possible buyout. Protalix Chief Executive David Aviezer has already said he expects to have a pact in place by the end of this year. The company has made waves in the Gaucher disease market with a successful late-stage trial of Uplyso. A likely contender to Cerezyme, the drug is being readied for an NDA after Genzyme announced problems with contamination at the facility that makes its extraordinarily expensive drug.

- read the report from Reuters

Related Articles:
Protalix boosted by late-stage Gaucher success
Protalix gets fast track for its red-hot Gaucher drug
Protalix shares rocket after FDA approves temp drug use
FDA turns to Protalix for new Gaucher drug